Stock Trading Canary

Snapshot date: 2026-10-18 · Built: 2026-10-19T15:57:46+00:00 · Publication status: REVIEW

← United States · 中文

COMPANY RESEARCH

Oncology Institute, Inc.

TOI · United States · Healthcare

INSIDER SIGNAL

Insider activity score：41.6 / 100

1 insiders · 6 purchase events · $333k net purchases

US #800 · United States #800

WHY THIS SIGNAL?

Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35

How many distinct insiders bought in the cluster

Purchase size+12.8 / 25

Purchase value relative to company size and liquidity

Role+6.0 / 20

The seniority and relevance of participating insiders

Recency+2.3 / 10

How recently the purchases occurred

Conviction+5.5 / 10

How clearly buying stands out from other activity

What is holding the score back?

  • ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
  • ⚠ Insider role contributes less on the current role scale
  • ⚠ Purchase activity is becoming less recent
  • ⚠ Buying conviction is reduced by concurrent selling

The role contribution follows the US model's seniority ladder.

BUYING PROFILE

6 events · 1 insiders · 180d

Cluster 0%Repeat 100%Independent 0%Large 0%

Percentages are mutually exclusive and sum to 100%.

Buying concentration

100%

Largest buyer：Chernett Jorey · 609k USD
Gross qualified purchase transaction-line value：609k USD

The headline $ total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.

This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.

Key purchase quotes (filing currency)

FilerPrice per unitTrade date
Chernett Jorey5.27 USDJul 21, 2026
Chernett Jorey5.85 USDJul 10, 2026
Chernett Jorey4.05–4.09 USDMay 19, 2026
Model details

Cluster breakdown (does not change the score)

15-day buyer breadth (count)
1 distinct reported filers
Peak time window
2026-05-19 to 2026-05-20
Current breadth input
0.200 (capped at 4+ buyers)
Buyer independence
Not yet measured; related-party fields are not cross-market comparable

What the filings show

Insider timeline

One insider bought, 6 times, the latest (21 Jul).

Podnos YalePodnos YaleChief Medical OfficerExecutiveChernett JoreyChernett JoreyTenPercentOwnerAssociated person2026-06-08 · Podnos Yale · sale · 126,166 USD2026-07-14 · Podnos Yale · sale · 150,358 USD2026-05-19 · Chernett Jorey · purchase · 142,950 USD2026-05-20 · Chernett Jorey · purchase · 136,345 USD2026-06-04 · Chernett Jorey · purchase · 57,000 USD2026-06-23 · Chernett Jorey · purchase · 90,360 USD2026-07-10 · Chernett Jorey · purchase · 87,750 USD2026-07-21 · Chernett Jorey · purchase · 94,860 USD2026-04-20 to 2026-04-26: 74 companies2026-04-27 to 2026-05-03: 96 companies2026-05-04 to 2026-05-10: 151 companies2026-05-11 to 2026-05-17: 232 companies2026-05-18 to 2026-05-24: 259 companies2026-05-25 to 2026-05-31: 171 companies2026-06-01 to 2026-06-07: 192 companies2026-06-08 to 2026-06-14: 172 companies2026-06-15 to 2026-06-21: 163 companies2026-06-22 to 2026-06-28: 108 companies2026-06-29 to 2026-07-05: 93 companies2026-07-06 to 2026-07-12: 80 companies2026-07-13 to 2026-07-19: 79 companies2026-07-20 to 2026-07-26: 70 companies2026-07-27 to 2026-08-02: 77 companies2026-08-03 to 2026-08-09: 131 companies2026-08-10 to 2026-08-16: 200 companies2026-08-17 to 2026-08-23: 218 companies2026-08-24 to 2026-08-30: 184 companies2026-08-31 to 2026-09-06: 175 companies2026-09-07 to 2026-09-13: 139 companies2026-09-14 to 2026-09-20: 186 companies2026-09-21 to 2026-09-27: 134 companies2026-09-28 to 2026-10-04: 130 companies2026-10-05 to 2026-10-11: 73 companies2026-10-12 to 2026-10-18: 72 companiesCompanies disclosing purchases, per weekMayJunJulAugSepOct

Tap an item for what it means.

●A purchase: the bigger the dot, the more was bought

Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.

×A sale

A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.

▂Grey bars: companies across United States disclosing purchases each week

A taller bar is a week in which more companies disclosed insider purchases.

This company: insiders buying per month, last 12 months

Nov
Dec
Jan
Feb
1Mar
1Apr
1May
1Jun
1Jul
Aug
Sep
Oct

Darker bars are inside the 180-day window above.

Who traded

InsiderRolePurchasesSalesBoughtFirst purchaseShare price since
Podnos YaleExecutive—2———
Chernett JoreyAssociated person6—609.3k USD2026-05-19—

Purchases against sales

69%purchases
Purchases69%609.3k USD · 7 line(s) · 1 insider(s)
Sales31%276.5k USD · 3 line(s) · 1 insider(s)

Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.

BULL VS BEAR

Two readings of this buying

The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.

Where the evidence comes from

  • The insider purchases themselvesBearone buyer only, insiders also sold, purchase added little to the holding5 checked, under the threshold · 1 missing
  • Share price and tradingno data held
  • Short sellersno data held
  • Company results2 missing
  • Company actionsno data held

Bull case · the buying is informative

Nothing held here goes beyond the fact that an insider bought.

Bear case · discount it

  • Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.
  • Insiders also sold $277k in the same 180 days, 45% of the amount bought.
  • 6 of 6 purchase filings state the shares held before and after. Each purchase added less than 1% to what the filer already held; the largest took a holding from 10,529,358 to 10,567,858 shares (+0.37%). A holding here is one way of owning the shares: directly, or through one named trust or entity.

Evidence still missing

  • No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
  • The company's market value is not captured, so the purchases cannot be stated as a share of the business or of its trading volume.
  • No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.
Checked and under the threshold: 5, 1 close to it
  • EitherThe latest purchase is 89 days old. Bull up to 14 days, bear from 90. close to the threshold
  • Either1 insider bought in the last 180 days and 1 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
  • EitherNet purchases of $333k in 180 days. Bull from $1.0M, bear when all purchases total under $25k.
  • BearNone of the 6 purchase filings ticks Form 4's 10b5-1 box.
  • BearNo insider filing in the last 180 days opened a hedge on this stock.

Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.

Why this score? · Model details

Priority = 100 × Σ(fixed weight × 0–1 rule-based input)

FactorWeightThis company inputPoint contribution
15-day buyer breadth (count)35%0.2007.0
Qualified-buy size25%0.51312.8
Role informativeness (inverted)20%0.70014.0
Recency10%0.2272.3
Buy/sell conviction10%0.5465.5

This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.

Signal history

41.6 / 100

Latest recorded score

↑ +4.7 ptssince the first recorded snapshot on 2026-10-12; 6 calendar days observed
Recorded snapshots
6
First snapshot
2026-10-12

There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.

Why did it change?

Less than 30 days of comparable history is available, so factor movement is not yet decomposed.

Signal score history

Fixed 0–100 scale; dates are spaced by calendar time.

02550751002026-10-12 · 36.92026-10-13 · 36.92026-10-14 · 41.82026-10-15 · 41.82026-10-16 · 41.72026-10-18 · 41.6Oct 12Oct 13Oct 14Oct 16Oct 18

Recent recorded points

  1. 36.9
  2. 36.9
  3. 41.8
  4. 41.7
  5. 41.6
View all recorded scores
Snapshot dateSignal score
2026-10-1236.9
2026-10-1336.9
2026-10-1441.8
2026-10-1541.8
2026-10-1641.7
2026-10-1841.6

Sector context

Healthcare

Buying breadth
4.1% (42 / 1,029 issuers)
Sector rank
#8 / 13

This is sector-level research context. It does not affect the Insider Signal or ranking.

View US sector research →

Insider profile outcomes

Historical performance following insider filings. The company role is translated below each name while preserving the original title.

Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.

Chernett JoreyTenPercentOwner
First purchase in 12M
3/36
Large purchase ≥ $100k
24/36
Cluster buying · 15D
0/36
Buying the dip · ≥20% below prior 52W high
Not classifiable
Routine / opportunistic
Not classifiable
Hively BradDirector
First purchase in 12M
0/2
Large purchase ≥ $100k
0/3
Cluster buying · 15D
1/3
Buying the dip · ≥20% below prior 52W high
Not classifiable
Routine / opportunistic
Not classifiable
BARASCH RICHARD ADirector
First purchase in 12M
Not classifiable
Large purchase ≥ $100k
1/1
Cluster buying · 15D
1/1
Buying the dip · ≥20% below prior 52W high
Not classifiable
Routine / opportunistic
Not classifiable

Insiders' buying price vs the latest close

No daily prices have been captured for this stock yet.

Buying size vs market trading

Complete price and volume history is not yet available.

Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable

Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.

Latest news

Unfold all 4 additional news item(s)

News is reader context only; it does not change the score or inclusion.

Regulatory filings

Unfold all 47 filings

Results and insider purchases

Results (8-K)Bought within 5 sessionsBought within 20 sessionsBuyers, 20 sessions before
2026-08-0616:32 ET · after the closeFirst session 2026-08-07NoneNone1
2026-05-0716:12 ET · after the closeFirst session 2026-05-08None1 · $336.3KChernett Jorey0
2026-03-1216:05 ET · after the closeFirst session 2026-03-131 · $1.2MChernett Jorey1 · $2.0MChernett Jorey0
2026-01-1208:00 ET · before the openNoneNone0

Results dates are the company's 8-K filings to the SEC under Item 2.02 (results of operations); one filed after the close counts from the next session. Purchases are open-market buys reported on Form 4 (code P), by trade date; a Form 4 can arrive two business days after the trade, so the latest days can still fill in. Facts only; this does not change the score or rank.

Ownership and trading-plan context

Direct / indirect ownershipUnavailable
10b5-1 filing evidenceUnavailable
Evidence retrievedUnavailable

These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.

Filing evidence

These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.

Excluded transactions & classification

12 qualifying purchase disclosure(s) · 15 transaction line(s)

Mar 27, 2026Open market purchase
Chernett Jorey · TenPercentOwner
Common Stock · 27429.0 shares × 2.96 USD · 81189.84 USD
Open filing
Mar 26, 2026Open market purchase
Chernett Jorey · TenPercentOwner
Common Stock · 50000.0 shares × 3.15 USD · 157500.0 USD
Open filing
Mar 24, 2026Open market purchase
Chernett Jorey · TenPercentOwner
Common Stock · 125000.0 shares × 3.11 USD · 388750.0 USD
Open filing
Unfold all 12 remaining filing row(s)
Transaction datePublishedFilerRoleTransactionInstrumentPrice (local currency)Quote currencyVolumeReported value (local currency)Source
2026-03-202026-03-23Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock3.35 USDUSD25000.083750.0 USDOpen filing
2026-03-172026-03-17Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock3.42 USDUSD75000.0256500.0 USDOpen filing
2026-03-162026-03-17Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock3.29 USDUSD60985.0200640.65 USDOpen filing
2026-03-132026-03-17Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock2.92 USDUSD263000.0767960.0 USDOpen filing
2026-06-232026-06-24Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock5.02 USDUSD18000.090359.99999999999 USDOpen filing
2026-06-042026-06-05Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock4.75 USDUSD12000.057000.0 USDOpen filing
2026-05-202026-05-21Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock4.07 USDUSD33500.0136345.0 USDOpen filing
2026-05-192026-05-21Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock4.05 USDUSD5000.020250.0 USDOpen filing
2026-05-192026-05-20Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock4.09 USDUSD30000.0122700.0 USDOpen filing
2026-04-092026-04-13Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock3.1 USDUSD20000.062000.0 USDOpen filing
2026-07-212026-07-22Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock5.27 USDUSD18000.094859.99999999999 USDOpen filing
2026-07-102026-07-13Chernett JoreyTenPercentOwnerOpen market purchaseCommon Stock5.85 USDUSD15000.087750.0 USDOpen filing

Showing 15 of 15 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Other disclosed transactions · excluded from score

View 50 other transaction(s)

Dec 15, 2025Open market sale
Hively Brad · Director
Common Stock · 13333.0 shares × 3.77 USD · 50265.41 USD
Open filing
Nov 20, 2025Grant or award
McGeorge Anne · Director
Common Stock · 67901.0 shares × 0.0 USD · 0.0 USD
Open filing
Nov 20, 2025Grant or award
McGeorge Anne · Director
Common Stock · 40123.0 shares × 0.0 USD · 0.0 USD
Open filing
Unfold all 47 remaining filing row(s)
Transaction datePublishedFilerRoleTransactionInstrumentPrice (local currency)Quote currencyVolumeReported value (local currency)Source
2025-11-202025-11-24Kaushal MohitDirectorGrant or awardCommon Stock0.0 USDUSD40123.00.0 USDOpen filing
2025-11-202025-11-24Kaushal MohitDirectorGrant or awardCommon Stock0.0 USDUSD50926.00.0 USDOpen filing
2025-11-202025-11-24Ling GabrielDirectorGrant or awardCommon Stock0.0 USDUSD37037.00.0 USDOpen filing
2025-11-202025-11-24Ling GabrielDirectorGrant or awardCommon Stock0.0 USDUSD46296.00.0 USDOpen filing
2025-11-202025-11-24Johnson Karen MarieDirectorGrant or awardCommon Stock0.0 USDUSD37037.00.0 USDOpen filing
2025-11-202025-11-24Johnson Karen MarieDirectorGrant or awardCommon Stock0.0 USDUSD47840.00.0 USDOpen filing
2025-11-202025-11-24Pacala Mark LDirectorGrant or awardCommon Stock0.0 USDUSD35494.00.0 USDOpen filing
2025-11-202025-11-24Pacala Mark LDirectorGrant or awardCommon Stock0.0 USDUSD46296.00.0 USDOpen filing
2025-11-202025-11-24Hively BradDirectorGrant or awardCommon Stock0.0 USDUSD32407.00.0 USDOpen filing
2025-11-202025-11-24Hively BradDirectorGrant or awardCommon Stock0.0 USDUSD41667.00.0 USDOpen filing
2025-11-182025-11-20Pacala Mark LDirectorOpen market saleCommon Stock4.0 USDUSD46630.0186520.0 USDOpen filing
2025-11-182025-11-20Pacala Mark LDirectorOpen market saleCommon Stock4.0 USDUSD2160.08640.0 USDOpen filing
2025-11-182025-11-20Pacala Mark LDirectorOpen market saleCommon Stock4.0 USDUSD1210.04840.0 USDOpen filing
2025-11-182025-11-20M33 Growth I GP LLC; M33 Growth I L.P.; TOI M, LLCDirectorOther acquisition or dispositionCommon Stock—USD2500000.00.0 USDOpen filing
2025-11-182025-11-20M33 Growth I GP LLC; M33 Growth I L.P.; TOI M, LLCDirectorOther acquisition or dispositionCommon Stock—USD590892.00.0 USDOpen filing
2025-11-182025-11-20M33 Growth I GP LLC; M33 Growth I L.P.; TOI M, LLCDirectorOther acquisition or dispositionCommon Stock—USD11818.00.0 USDOpen filing
2025-11-182025-11-20Ling GabrielDirectorOther acquisition or dispositionCommon Stock—USD141149.00.0 USDOpen filing
2025-11-172025-11-19Virnich DanielChief Executive OfficerGrant or awardCommon Stock0.0 USDUSD6464.00.0 USDOpen filing
2025-11-172025-11-19Podnos YaleChief Medical OfficerGrant or awardCommon Stock0.0 USDUSD2086.00.0 USDOpen filing
2025-11-172025-11-19Carter Robert RossChief Financial OfficerGrant or awardCommon Stock0.0 USDUSD195.00.0 USDOpen filing
2025-11-122025-11-14Virnich DanielChief Executive OfficerGrant or awardCommon Stock0.0 USDUSD6211.00.0 USDOpen filing
2025-11-122025-11-14Podnos YaleChief Medical OfficerGrant or awardCommon Stock0.0 USDUSD306.00.0 USDOpen filing
2025-11-122025-11-14Podnos YaleChief Medical OfficerGrant or awardCommon Stock0.0 USDUSD1202.00.0 USDOpen filing
2026-03-172026-03-18Virnich DanielChief Executive OfficerOther acquisition or dispositionCommon Stock3.59 USDUSD11834.042484.06 USDOpen filing
2026-03-172026-03-18Carter Robert RossChief Financial OfficerOther acquisition or dispositionCommon Stock3.59 USDUSD1314.04717.26 USDOpen filing
2026-03-172026-03-18Podnos YaleChief Medical OfficerOther acquisition or dispositionCommon Stock3.59 USDUSD3420.012277.8 USDOpen filing
2026-01-022026-01-06Carter Robert RossChief Financial OfficerOther acquisition or dispositionCommon Stock3.67 USDUSD244.0895.48 USDOpen filing
2026-01-022026-01-05Carter Robert RossChief Financial OfficerOpen market saleCommon Stock3.56 USDUSD247.0879.32 USDOpen filing
2026-06-082026-06-09Podnos YaleChief Medical OfficerOpen market saleCommon Stock5.38 USDUSD23451.0126166.38 USDOpen filing
2026-05-212026-05-22Podnos YaleChief Medical OfficerOther acquisition or dispositionCommon Stock4.47 USDUSD1805.08068.349999999999 USDOpen filing
2026-05-212026-05-22Virnich DanielChief Executive OfficerOther acquisition or dispositionCommon Stock4.47 USDUSD23058.0103069.26 USDOpen filing
2026-05-212026-05-22Carter Robert RossChief Financial OfficerOther acquisition or dispositionCommon Stock4.47 USDUSD1604.07169.879999999999 USDOpen filing
2026-04-162026-04-16Kaushal MohitDirectorOpen market saleCommon Stock3.5 USDUSD38433.0134515.5 USDOpen filing
2026-04-142026-04-16Kaushal MohitDirectorOpen market saleCommon Stock3.5 USDUSD57286.0200501.0 USDOpen filing
2026-07-272026-07-29Kaushal MohitDirectorGrant or awardCommon Stock0.0 USDUSD33133.00.0 USDOpen filing
2026-07-272026-07-29McGeorge AnneDirectorGrant or awardCommon Stock0.0 USDUSD41165.00.0 USDOpen filing
2026-07-272026-07-29Pacala Mark LDirectorGrant or awardCommon Stock0.0 USDUSD30120.00.0 USDOpen filing
2026-07-272026-07-29STOLPER MARKDirectorGrant or awardCommon Stock0.0 USDUSD31124.00.0 USDOpen filing
2026-07-272026-07-29TZOUMAKAS KIMBERLY JODirectorGrant or awardCommon Stock0.0 USDUSD29116.00.0 USDOpen filing
2026-07-272026-07-29Hively BradDirectorGrant or awardCommon Stock0.0 USDUSD27108.00.0 USDOpen filing
2026-07-272026-07-29Johnson Karen MarieDirectorGrant or awardCommon Stock0.0 USDUSD31124.00.0 USDOpen filing
2026-07-142026-07-16Podnos YaleChief Medical OfficerExercise of derivative securityCommon Stock2.0 USDUSD5478.010956.0 USDOpen filing
2026-07-142026-07-16Podnos YaleChief Medical OfficerOpen market saleCommon Stock6.35 USDUSD5478.034785.299999999996 USDOpen filing
2026-07-142026-07-16Podnos YaleChief Medical OfficerOpen market saleCommon Stock6.43 USDUSD17974.0115572.81999999999 USDOpen filing
2026-07-142026-07-16Podnos YaleChief Medical OfficerExercise of derivative securityCommon Stock1.87 USDUSD17974.033611.380000000005 USDOpen filing
2026-07-072026-07-09TZOUMAKAS KIMBERLY JODirectorGrant or awardCommon Stock0.0 USDUSD17185.00.0 USDOpen filing
2026-07-072026-07-09STOLPER MARKDirectorGrant or awardCommon Stock0.0 USDUSD25833.00.0 USDOpen filing

Showing 50 of 50 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Snapshot & identity

Snapshot date
2026-10-18
Ticker
TOI
ISIN
—
Sector
Healthcare
Industry
—

Share this page

Save share image

The image states the stored facts and the snapshot date. It is not a recommendation.

Company logos by Parqet

Signal outcomes

Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.

HorizonStatusResult
5DAwaiting maturity—
20DAwaiting maturity—
60DAwaiting maturity—
120DAwaiting maturity—

How to read Form 4 transaction codes

CodeInterpretationScreen treatment
POpen-market / private purchaseBuy evidence when the security is qualifying equity
SSaleSell evidence when the security is qualifying equity
AGrant / awardContext only
FTax-related withholdingContext only
MOption exerciseContext only
GGiftContext only
J / LOther / non-directionalContext only

P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.